1 citations
,
October 2020 in “Current Drug Discovery Technologies” This study investigated various synthesized 5-reductase inhibitors and found that compound 6 had the highest anti-androgenic activity and receptor affinity compared to finasteride, showing potential due to its improved efficacy and bioavailability for further research in treating lower urinary tract symptoms.
November 2023 in “ACS Omega” This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.
In this study, finasteride reduced the severity of dopaminergic behavior manifestations in rats without causing extrapyramidal side effects, unlike other antidopaminergic agents.
This review discusses the potential benefits of the Restolin Hair Supplement for hair growth and reports no clinical results, with the authors noting that the claims are not supported by FDA approval or clinical trials.
70 citations
,
June 1993 in “Biochemistry” This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.